Preface

The core evidence-based message is that consolidated, adequate-duration, regular sleep (approximately 7–9 h, with a nadir of risk near 7–7.7 h device-measured) is one of the most robustly supported modifiable determinants of all-cause mortality and healthspan, and that cognitive behavioural therapy for insomnia (CBT-I) is the only guideline-endorsed first-line therapeutic, with all pharmacological and device-based “optimisation” strategies being adjunctive, short-term or frankly experimental in the longevity context.[1][2][3] Almost all mortality/biological-ageing data are observational; there are no RCTs demonstrating that manipulating sleep extends human lifespan, so longevity-specific claims rest on surrogate and epidemiological evidence only.


1. Scope

– Covered: Assessment and optimisation of sleep duration, quality, timing and regularity in community-dwelling adults attending a longevity clinic; CBT-I; sleep-hygiene/environmental measures; light and circadian interventions; melatonin and prescription hypnotics (orexin antagonists, low-dose doxepin, ramelteon); use of ageing biomarkers as monitoring surrogates.

– Positioned as adjunctive to conventional primary/secondary care, not a replacement for it.

– Not covered in depth: Diagnosis and management of primary sleep pathology requiring specialist referral — obstructive sleep apnoea (OSA), narcolepsy, REM sleep behaviour disorder, restless legs syndrome; paediatric sleep; sleep in pregnancy. These are flagged as referral triggers rather than clinic-managed conditions.

– Excluded: Benzodiazepines, Z-drugs, sedating antihistamines and other agents on the AGS Beers “avoid” list as longevity interventions.[3]



2. Background and pathophysiology

Biological rationale (robust human mechanistic evidence):

– Circadian biology: Ageing reduces melatonin amplitude and secretion, suprachiasmatic nucleus output, and circadian robustness, producing phase advance, fragmentation and reduced slow-wave sleep. Circadian disruption is prospectively associated with neurodegenerative disease.[4][5][6]

– Inflammageing: Even a single night of partial sleep deprivation upregulates peripheral-blood transcripts of the DNA-damage response and cellular senescence (e.g. CDKN2A/p16^INK4a) and raises IL-6, TNF-α and CRP — mechanisms plausibly linking poor sleep to age-related morbidity.[7][8]

– Cardiometabolic: Short sleep impairs insulin sensitivity, appetite-hormone regulation and physical activity, contributing to cardiometabolic risk; the sleep–CVD relationship is bidirectional.[9][10]

– Biological-ageing surrogates: Observational and Mendelian-randomisation data associate short (and, less consistently, long) sleep with accelerated PhenoAge/BioAge and shorter leukocyte telomere length, with an optimum near 7 h/day; MR supports a causal deleterious effect of insufficient (but not clearly excessive) sleep. Insomnia and OSA are meta-analytically associated with shorter telomeres and epigenetic age acceleration, which may be partly reversible.[11][12][13]

Preclinical / lower-certainty (clearly separated):

– Senolytics for age-related sleep decline: Only early mechanistic interest in targeting cellular senescence to preserve circadian rhythm/sleep — no robust human data; mechanistic plausibility only.[14]

– Rodent and in-vitro data on melatonin as a mitochondrial protector and free-radical scavenger underpin much of the “anti-ageing” melatonin narrative but do not constitute human clinical evidence.[4]



3. Evidence base and grading

Evidence types available: multiple large prospective cohorts (UK Biobank, CHARLS, WHI, NHIS) including device-measured sleep; systematic reviews/meta-analyses of cohort data for mortality and ageing biomarkers; RCTs for CBT-I and for specific pharmacological/light interventions (mostly disease-specific, short-term, surrogate endpoints). No RCT has lifespan or hard longevity endpoints as its primary outcome.

GRADE-style certainty by outcome:

– All-cause mortality vs sleep duration — Moderate certainty. Meta-analysis of 79 cohorts: short sleep (<7 h) HR 1.14 (95% CI 1.10–1.18); long sleep (≥9 h) HR 1.34 (1.26–1.42). Device-based UK Biobank shows an inverse J-shape with nadir ~7.2–7.7 h. Downgraded for indirectness (observational, reverse causation, confounding by comorbidity — long sleep especially is a likely marker of illness) and residual confounding; upgraded for large, consistent dose–response. Strength: Strong recommendation to assess and support 7–9 h sleep as a longevity-relevant target. Because “long sleep” is largely a marker of underlying disease, do not recommend deliberate sleep extension beyond individual need; investigate long sleepers for occult illness.[1][2]

– Sleep quality/efficiency and regularity vs mortality — Moderate certainty. Accelerometer data: low sleep efficiency raises mortality and amplifies risk of long duration (HR up to 2.11); multidimensional “healthy sleep” pattern associates with 18–26% lower mortality and 1.5–3 years’ greater life expectancy. Strength: Strong recommendation to target quality/consolidation, not just hours.[15][16]

– Sleep and biological-ageing biomarkers (telomeres, epigenetic/PhenoAge) — Low-to-Moderate certainty. Consistent associations plus supportive MR, but biomarker change is a surrogate not validated to predict individual clinical benefit from an intervention. Strength: Only in research for using biomarker improvement as a treatment target.[11][12][13]

– CBT-I for chronic insomnia — High certainty (guideline-endorsed). First-line at all ages per AGS Beers, ACP and multiple societies; effective in person and digitally; superior to and safer than medication. Strength: Strong recommendation.[3][14][17]

– Melatonin/light for circadian & sleep outcomes in older adults — Low-to-Moderate certainty. RCT evidence for modest benefit (e.g. bright light attenuated cognitive/functional decline; melatonin 2.5 mg shortened sleep-onset latency by ~8 min and increased duration by ~27 min in institutionalised elderly) but heterogeneous, small, short and largely surrogate. Strength: Conditional recommendation (circadian disorders/select older adults); insufficient evidence to recommend melatonin routinely for insomnia disorder.[5][18][6][3]

– Sleep extension for cardiometabolic risk — Low certainty. Feasible with early signals; trials small, short (2–8 weeks), underpowered. Strength: Only in research / Conditional.[10]

– Prescription hypnotics (orexin antagonists, low-dose doxepin, ramelteon) — Low certainty for older adults; no longevity data. May be “safer but not completely safe,” short-term only; no formal efficacy/safety guidelines in older adults. Strength: Conditional, short-term, second-line after CBT-I.[3]

Publication bias: probable for melatonin, light and sleep-extension literature (small positive trials). Imprecision is the dominant limitation for all interventional (as opposed to epidemiological) outcomes.



4. Patient selection and indications

Who may benefit (inclusion):

– Adults with habitual short (<7 h) or fragmented/low-efficiency sleep, especially with cardiometabolic risk factors.[15][10]

– Middle-aged/older adults with insomnia disorder — CBT-I candidates.[3]

– Circadian misalignment (delayed/advanced sleep–wake phase, shift work, jet lag) — candidates for timed light ± melatonin.[5][6]

– Patients with established ASCVD — larger absolute mortality/life-expectancy gains from sleep-health optimisation.[16]

– Older adults with frailty or at risk of frailty, where poor/irregular sleep is associated with frailty progression.[8][19]

– Long sleepers (≥9 h): not a group to “extend”; treat as a screening flag for occult disease, depression or OSA.[1]

Exclusion / specialist-input groups:

– Suspected OSA, narcolepsy, RBD, significant restless legs — refer to sleep medicine before “optimising”; do not mask OSA with hypnotics.

– Untreated significant psychiatric illness, substance misuse, or hypnotic dependence — specialist input.

– Frail/multimorbid older adults — avoid sedative-hypnotics (falls, fracture, cognitive risk).[3][14]

Regulatory/ethical status:

– CBT-I, sleep hygiene, light exposure, exercise/behavioural timing: on-label/standard care.

– Melatonin: in the UK, prescription-only, licensed principally as prolonged-release (Circadin) for short-term insomnia in adults ≥55 and for certain paediatric/ASD indications; use for “anti-ageing”/longevity is off-label.[5]

– Orexin antagonists (daridorexant/Quviviq, lemborexant, suvorexant), low-dose doxepin, ramelteon: licensed for insomnia (availability varies in UK); any longevity/biomarker indication is off-label and experimental.[20][3]

– Senolytics for sleep, deliberate sleep extension for lifespan, biomarker-targeted dosing: only within research/registry frameworks with explicit informed consent.[14]



5. Assessment and baseline work-up

History and tools:

– Sleep history: habitual duration, timing, latency, awakenings, efficiency, chronotype, daytime function, napping; caffeine/alcohol/nicotine, medications affecting sleep (stimulants, SSRIs/MAOIs, lipophilic beta-blockers, glucocorticoids, diuretics).[14]

– Validated instruments: Insomnia Severity Index (ISI), Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale; STOP-Bang for OSA screening; PHQ-9/GAD-7 for mood; frailty screen (e.g. FRAIL/Clinical Frailty Scale) in older adults.[8][19]

– Sleep diary ± consumer/actigraphy for ≥1–2 weeks (device-measured sleep-period-time correlates most strongly with outcomes).[2]

Baseline investigations (tailored, proportionate):

– Cardiometabolic: BP, fasting glucose/HbA1c, lipids, waist circumference/BMI.[9][10]

– Consider TFTs, ferritin (restless legs), and evaluation for OSA where indicated (home sleep test/referral).

– Optional research/longevity biomarkers (interpret cautiously as surrogates, not endpoints): epigenetic age (PhenoAge/DNAm clocks), leukocyte telomere length, hs-CRP/IL-6.[11][12][13]

Risk stratification: stratify by (a) benefit likelihood (short/fragmented/irregular sleeper with cardiometabolic risk = higher expected benefit) and (b) harm risk (frailty, falls risk, polypharmacy, hypnotic history = higher harm from pharmacological approaches, favouring behavioural-only).

Baseline documentation: habitual/device-measured duration, efficiency, regularity (sleep midpoint variability), ISI/PSQI scores, chronotype, cardiometabolic panel, medication list, and any biomarker values, to enable meaningful follow-up.



6. Dosing regimens and practical implementation

Behavioural and environmental (robust human data / first-line):

– CBT-I: structured programme — sleep restriction, stimulus control, cognitive therapy, relaxation, sleep-hygiene education; typically 4–8 sessions, in-person or digital; first-line for chronic insomnia at all ages. Note: sleep hygiene alone is ineffective for chronic insomnia.[3][17]

– Sleep-hygiene/lifestyle package: consistent wake time; 7–9 h opportunity; dark, cool bedroom; limit caffeine after midday; avoid alcohol/nicotine within 3–4 h of bed; limit evening fluids; regular physical activity; intentional/limited napping.[14]

– Regularity: prioritise a stable sleep–wake schedule; irregularity and low efficiency independently predict mortality.[15][16]

Circadian/light and melatonin (conditional; longevity use off-label):

– Morning bright light (~≥1000 lux, whole-day/timed exposure in trials) for select older adults/dementia to support circadian function and mood; evening bright light for advanced sleep–wake phase disorder.[18][6][5]

– Melatonin (chronobiotic): immediate-release 0.5–5 mg ~1–3 h before target sleep onset (or ~5–6 h before current onset) for delayed sleep–wake phase disorder; low doses in late afternoon/early evening produce maximal phase advance. Advise not to take within 8 h of driving; clinical supervision advised. Prolonged-release melatonin is the UK-licensed short-term option in adults ≥55.[5]

Prescription hypnotics (short-term, second-line, off-label for longevity):

– Dual orexin receptor antagonists (daridorexant, lemborexant, suvorexant) and low-dose doxepin (≤6 mg) or ramelteon — preferred over benzodiazepines/Z-drugs in older adults, short-term, after CBT-I; no formal older-adult efficacy/safety guidelines exist.[20][3]

Require caution / research only:

– Deliberate sleep extension protocols and biomarker-guided dosing — extrapolated from early-phase/surrogate data.[11][10]

– Senolytics for sleep — preclinical only; do not offer outside trials.[14]



7. Monitoring, safety and follow-up

Monitoring plan:

– Clinical: repeat ISI/PSQI, sleep diary/actigraphy (duration, efficiency, regularity), daytime function, mood; cardiometabolic parameters where relevant.[2][9]

– Optional ageing biomarkers (hs-CRP, epigenetic age, telomere length) only as research surrogates, explicitly not as validated proof of clinical benefit.[11][12]

Timepoints: review at 2–4 weeks (behavioural adherence, hypnotic tolerability), 6–12 weeks (efficacy, taper any hypnotic), then 6–12-monthly for maintenance and cardiometabolic surveillance.

Adverse effects:

– Melatonin: generally well tolerated; daytime sedation, headache, dizziness; safety data limited, particularly in pregnancy/adolescents.[5]

– Orexin antagonists: somnolence/next-day impairment, abnormal dreams, rare sleep paralysis/complex sleep behaviours; caution with driving.[20]

– Low-dose doxepin/ramelteon: anticholinergic caution (doxepin), generally modest effects.[3]

– Benzodiazepines/Z-drugs/sedating antihistamines/TCAs: falls, fracture, cognitive impairment/dementia risk — avoid in older adults.[3][14]

– Light therapy: eye strain, headache, rare mania induction in bipolar disorder.

Actions for abnormal findings: persistent insomnia despite CBT-I → shared-decision short-term pharmacotherapy or specialist referral; excessive daytime sleepiness/loud snoring/witnessed apnoeas → sleep-medicine referral; long-sleep or new hypersomnolence → investigate for depression, OSA, occult disease.[1][9]

Interactions/special populations: melatonin — caution with CYP1A2 inhibitors (fluvoxamine) and anticoagulants; orexin antagonists — CYP3A4 interactions, dose-reduce with moderate inhibitors and in hepatic impairment, avoid in severe hepatic impairment.[20] Frailty/extremes of age — favour behavioural interventions, minimise sedatives.[3][14] Pregnancy/breastfeeding — melatonin/hypnotic safety data lacking; avoid unless specialist-directed.[5]



8. Contraindications and cautions

– Absolute: hypersensitivity to a chosen agent; untreated severe OSA masked by sedative hypnotics; severe hepatic impairment for orexin antagonists.[20]

– Relative / specialist advice: frailty and high falls risk; polypharmacy; history of hypnotic/substance dependence; bipolar disorder (bright light); significant hepatic/renal impairment; pregnancy/breastfeeding; occupations requiring night-time alertness (driving within 8 h of melatonin).[5][3][14]

– Harm likely > benefit with current evidence: benzodiazepines, Z-drugs, sedating antihistamines and TCAs as longevity sleep aids in older adults; senolytics or biomarker-targeted regimens outside research.[3][14]



9. Practical management scenarios

Scenario A — Middle-aged patient with multiple cardiometabolic risk factors and short/fragmented sleep. Offer optimisation — Strong recommendation.[1][16][10]

1. Assessment: sleep diary + actigraphy, ISI/PSQI, STOP-Bang, cardiometabolic panel.

2. Shared decision/consent: frame 7–9 h consolidated, regular sleep as a modifiable mortality/cardiometabolic-risk factor; note evidence is largely observational.

3. Initiation: CBT-I (digital acceptable) + sleep-hygiene/lifestyle package; treat/refer OSA if screen positive.[10][3]

4. Monitoring: 4- and 12-week review of ISI, efficiency, BP/HbA1c/lipids.

5. Escalate/stop: if insomnia persists after CBT-I, consider short-term orexin antagonist via shared decision; refer if OSA/other pathology emerges.

Scenario B — Older, frail patient with multimorbidity. Consider behavioural optimisation; avoid sedative-hypnotics — Strong recommendation against benzodiazepines/Z-drugs.[3][14]

1. Assessment: frailty and falls assessment, medication review for sleep-disrupting drugs, mood screen.[8][14]

2. Consent: emphasise non-pharmacological, falls-safe approach.

3. Initiation: CBT-I (adapted), timed morning bright light, activity, environmental measures; deprescribe offending medications.[18][14]

4. Monitoring: falls, cognition, daytime function at 4–12 weeks.

5. Escalate/stop: if pharmacotherapy unavoidable, short-term low-dose doxepin/ramelteon/orexin antagonist with caution; specialist geriatric/sleep input.[3]

Scenario C — Patient already under specialist care (e.g. treated ASCVD or on hypnotics), sleep optimisation as adjunct. Offer adjunctive behavioural optimisation — Strong recommendation; coordinate, don’t duplicate.[16][3]

1. Assessment: confirm existing diagnoses/treatments; reconcile medications with the specialist.

2. Consent: position as complementary; larger absolute benefit expected in ASCVD.[16]

3. Initiation: CBT-I + sleep-hygiene; plan hypnotic taper in collaboration where appropriate.

4. Monitoring: joint follow-up; ISI and cardiometabolic markers.

5. Escalate/stop: liaise with specialist for any medication change; do not alter specialist-prescribed therapy unilaterally.



10. Research gaps and future directions

– No hard-endpoint RCTs: whether intentionally improving sleep duration/quality/regularity reduces mortality or extends healthspan is untested; current longevity claims are epidemiological/surrogate.[1][2]

– Long-sleep paradox: disentangling reverse causation (illness driving long sleep) from any causal harm.[1][11]

– Biomarker validity: whether intervention-induced changes in epigenetic age/telomere length translate to clinical benefit — currently only in research.[11][12][13]

– Sleep extension: adequately powered, longer RCTs in habitual short sleepers with cardiometabolic risk.[10]

– Pharmacology in older/longevity populations: formal efficacy/safety data for orexin antagonists, melatonin and ramelteon are lacking.[3]

– Senolytics and circadian/sleep ageing: confined to preclinical work; restrict to well-designed trials/registries.[14]

Priority: conduct pragmatic RCTs of multidimensional sleep-health optimisation (CBT-I + circadian measures) with pre-specified cardiometabolic, cognitive, frailty and mortality endpoints, and enrol longevity-clinic patients receiving experimental regimens into registries.


Central Illustration Central Illustration. Li H, Liu Y, Sun B, et al. Healthy Sleep Patterns, Mortality, and Life Expectancy in Adults With and Without Atherosclerotic Cardiovascular Disease. JACC. Advances. 2026;5(2):102550. doi:10.1016/j.jacadv.2025.102550.

 

Figure 1 Figure 1. Li H, Liu Y, Sun B, et al. Healthy Sleep Patterns, Mortality, and Life Expectancy in Adults With and Without Atherosclerotic Cardiovascular Disease. JACC. Advances. 2026;5(2):102550. doi:10.1016/j.jacadv.2025.102550.

References

1. Imbalanced Sleep Increases Mortality Risk by 14-34%: A Meta-Analysis. Ungvari Z, Fekete M, Varga P, et al. GeroScience. 2025;47(3):4545-4566. doi:10.1007/s11357-025-01592-y.
2. Dose-Response Associations Between Sleep Duration and Health Outcomes in Adults: Comparison Between Self-Reported and Device-Based Measures. Chaput JP, Biswas RK, Ahmadi M, et al. Sleep. 2026;:zsag193. doi:10.1093/sleep/zsag193.
3. Alternative Treatments to Selected Medications in the 2023 American Geriatrics Society Beers Criteria®. Steinman MA. Journal of the American Geriatrics Society. 2025;73(9):2657-2677. doi:10.1111/jgs.19500.
4. Rhythms of Life: Melatonin, Nutrition, Sleep, and Antioxidant Strategies for Healthy Aging. Drăgoi CM, Dumitrescu IB, Nicolae AC. Frontiers in Neuroscience. 2026;20:1736978. doi:10.3389/fnins.2026.1736978.
5. Circadian Rhythms and Disorders of the Timing of Sleep. Meyer N, Harvey AG, Lockley SW, Dijk DJ. Lancet (London, England). 2022;400(10357):1061-1078. doi:10.1016/S0140-6736(22)00877-7.
6. Association Between Circadian Rhythms and Neurodegenerative Diseases. Leng Y, Musiek ES, Hu K, Cappuccio FP, Yaffe K. The Lancet. Neurology. 2019;18(3):307-318. doi:10.1016/S1474-4422(18)30461-7.
7. Sleep and inflammation: partners in sickness and in health. Irwin MR. Nature Reviews. Immunology. 2019;19(11):702-715. doi:10.1038/s41577-019-0190-z.
8. Association between nighttime sleep duration trajectories and frailty in middle-aged and older adults: A work-in-progress model based on a CHARLS cohort. Zhou Y, Guo X, Dong S, et al. PloS One. 2025;20(12):e0339843. doi:10.1371/journal.pone.0339843.
9. Contributions of the Women’s Health Initiative to Cardiovascular Research: JACC State-of-the-Art Review. LaMonte MJ, Manson JE, Anderson GL, et al. Journal of the American College of Cardiology. 2022;80(3):256-275. doi:10.1016/j.jacc.2022.05.016.
10. Sleep Extension and Cardiometabolic Health: What It Is, Possible Mechanisms and Real-World Applications. Duraccio KM, Kamhout S, Baron KG, Reutrakul S, Depner CM. The Journal of Physiology. 2024;602(23):6571-6586. doi:10.1113/JP284911.
11. Evaluating the Nonlinear Effects of Sleep Duration on Biological Aging Across Phenotypic, Genomic, and Epigenomic Data. Wu X, Zhao X, Ge A, et al. Aging. 2025;17(8):2126-2151. doi:10.18632/aging.206306.
12. Circulating Markers of Biological Aging Associated With Obstructive Sleep Apnea or Insomnia in Adults: A Systematic Review and Meta-Analysis. Chang THC, Hicks JB, Izadi Z, et al. Sleep Medicine Reviews. 2026;86:102255. doi:10.1016/j.smrv.2026.102255.
13. Sleep and Aging: The Role of DNA Methylation. Davinelli S, Scapagnini G, Medoro A. Experimental Gerontology. 2026;222:113205. doi:10.1016/j.exger.2026.113205.
14. Life’s Essential 8: Optimizing Health in Older Adults. Kumar M, Orkaby A, Tighe C, et al. JACC. Advances. 2023;2(7):100560. doi:10.1016/j.jacadv.2023.100560.
15. Joint Associations of Device-Measured Sleep Duration and Efficiency With All-Cause and Cause-Specific Mortality: A Prospective Cohort Study of 90 398 UK Biobank Participants. Liang YY, Ai S, Xue H, et al. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2023;78(9):1717-1724. doi:10.1093/gerona/glad108.
16. Healthy Sleep Patterns, Mortality, and Life Expectancy in Adults With and Without Atherosclerotic Cardiovascular Disease. Li H, Liu Y, Sun B, et al. JACC. Advances. 2026;5(2):102550. doi:10.1016/j.jacadv.2025.102550.
17. Comparative efficacy of non‐pharmacological interventions on sleep quality in old adults: A systematic review and network meta‐analysis. Chang H, Chen Y, Wang Z. Journal of Clinical Nursing. 2024;33(5):1948-1957. doi:10.1111/jocn.17086.
18. Effect of Bright Light and Melatonin on Cognitive and Noncognitive Function in Elderly Residents of Group Care Facilities: A Randomized Controlled Trial. Riemersma-van der Lek RF, Swaab DF, Twisk J, et al. JAMA. 2008;299(22):2642-55. doi:10.1001/jama.299.22.2642.
19. Weekend catch-up sleep and frailty in US adults: a cross-sectional study from NHANES 2017–2020. Yao H, Wang H, Li T, et al. BMC Public Health. 2025;25(1):1481. doi:10.1186/s12889-025-22793-2.
20. FDA Orange Book. FDA Orange Book.